DAFTAR PUSTAKA

1. Sutanto YS, Murti PWK, Reviono R, Probandari AN, Kurniawan H. Determinants of Delay in Diagnosis and Treatment in Multi Drug-Resistant Tuberculosis Patients in Health Facilities. Indones J Med. 2021;6(1):14–22.

2. Puranik S, Harlow C, Martin L, Coleman M, Russell G, Park M, et al. Monitoring prolongation of QT interval in patients with multidrug-resistant tuberculosis and non-tuberculous mycobacterium using mobile health device AliveCor [Internet]. J Clin Tuberc Other Mycobact Dis [Internet]. Elsevier Ltd; 2022;26(December 2021):100293. Available from: https://doi.org/10.1016/j.jctube.2021.100293

3. Kusmiati T, Mertaniasih NM, Putranto JNE, Suprapti B, Krisdanti DPA, Kusumastrini YDS, et al. Factors that contribute to the QTc interval prolongation in DR-TB patients on STR regimen. Indian J Forensic Med Toxicol. 2021;15(1):1605–12.

4. Wotale TW, Lelisho ME, Negasa BW, Tareke SA, Gobena WE, Amesa EG. Identifying risk factors for recurrent multidrug resistant tuberculosis based on patient's record data from 2016 to 2021: retrospective study. Sci Rep. 2024;14(1):23912.

5. Kemenkes RI. Pengobatan Tuberkulosis Resistan Obat dengan Panduan BPaL/M. 2023 p. 3.

6. Duarte R, Munsiff SS, Nahid P, Saukkonen JJ, Winston CA, Abubakar I, et al. Updates on the Treatment of Drug-Susceptible and Drug-Resistant Tuberculosis An Official ATS/CDC/ERS/IDSA Clinical Practice Guideline. Am J Respir Crit Care Med. 2025;211(1):15–33.

7. Pakan S. Petunjuk Teknis. 2007 .

8. Pai H, Ndjeka N, Mbuagbaw L, Kaniga K, Birmingham E, Mao G, et al. Bedaquiline safety, efficacy, utilization and emergence of resistance following treatment of multidrug-resistant tuberculosis patients in South Africa: a retrospective cohort analysis [Internet]. BMC Infect Dis [Internet]. BioMed Central; 2022;22(1):1–15. Available from: https://doi.org/10.1186/s12879-022-07861-x

9. Farid Thariqulhaq M, Yunis Miko Wahyono T. the Effectiveness and Safety of Bedaquiline-Containing Regimens in the Treatment of Patients With Multi-Drug Resistant Tuberculosis (Mdr-Tb): a Systematic Literature Review. J EduHealth. 2023;14(3):1382–92.

10. Oliveira de Souza LM. Electrocardiographic change: prolongation of the QT interval, imminent risk of sudden death. J Cardiol Curr Res. 2024;17(2):53–4.

11. Johnson JN, Ackerman MJ. QTc: How long is too long? Br J Sports Med. 2009;43(9):657–62.

12. Letsas K, Tsikrikas S, Letsas GP, Sideris A. Drug-Induced Proarrhythmia: QT Interval Prolongation and Torsades de Pointes. Hosp Chronicles. 2011;6(3):118–22.

13. Nachimuthu S, Assar MD, Schussler JM. Drug-induced QT interval prolongation: Mechanisms and clinical management. Ther Adv Drug Saf. 2012;3(5):241–53.

14. Cardiomyopathies D. Drug-Induced Cardiomyopathies. 2007;

15. Buckner CA, Lafrenie RM, Dénommée JA, Caswell JM, Want DA, Gan GG, et al. We are IntechOpen , the world ' s leading publisher of Open Access books Built by scientists , for scientists TOP 1 % [Internet]. Intech [Internet]. 2016;11(tourism):13. Available from: https://www.intechopen.com/books/advanced-biometric-technologies/liveness-detection-in-biometrics

16. Cho Y. Management of patients with long QT syndrome. Korean Circ J. 2016;46(6):747–52.

17. Ali AM, Radtke KK, Hesseling AC, Winckler J, Schaaf HS, Draper HR, et al. QT Interval Prolongation with One or More QT-Prolonging Agents Used as Part of a Multidrug Regimen for Rifampicin- Resistant Tuberculosis Treatment: Findings from Two Pediatric Studies. Antimicrob Agents Chemother. American Society for Microbiology; 2023;67(7).

18. Huerga H, Khan U, Bastard M, Mitnick CD, Lachenal N, Khan PY, et al. Safety and Effectiveness Outcomes From a 14-Country Cohort of Patients With Multi-Drug Resistant Tuberculosis Treated Concomitantly With Bedaquiline,

Delamanid, and Other Second-Line Drugs. Clin Infect Dis. 2022;75(8):1307–14.

19. Sherazi S, Disalle M, Daubert JP, Shah AH. Moxifloxacin-induced torsade de pointes. 2008;15(1):71–3.

20. Koide T, Shiba M, Tanaka K, Muramatsu M, Ishida S, Kondo Y, et al. Severe QT interval prolongation associated with moxifloxacin: a case report. Cases J. 2008;1(1):2–5.

21. Guglielmetti L, Tiberi S, Burman M, Kunst H, Wejse C, Togonidze T, et al. QT prolongation and cardiac toxicity of new tuberculosis drugs in Europe: A Tuberculosis Network European Trialsgroup (TBnet) study. Eur Respir J. 2018;52(2):10–3.

22. Padmapriyadarsini C, Vohra V, Bhatnagar A, Solanki R, Sridhar R, Anande L, et al. Bedaquiline, Delamanid, Linezolid, and Clofazimine for Treatment of Pre-extensively Drug-Resistant Tuberculosis [Internet]. Clin Infect Dis [Internet]. Oxford University Press; 2023;76(3):E938–46. Available from: https://doi.org/10.1093/cid/ciac528

23. Haeusler IL, Chan XHS, Guérin PJ, White NJ. The arrhythmogenic cardiotoxicity of the quinoline and structurally related antimalarial drugs: A systematic review. BMC Med. 2018;16(1):1–13.

24. Isralls S, Baisley K, Ngam E, Grant AD, Millard J. QT Interval Prolongation in People Treated with Bedaquiline for Drug-Resistant Tuberculosis under Programmatic Conditions: A Retrospective Cohort Study. Open Forum Infect Dis. 2021;8(8):1–10.

25. Simanjuntak AM, Aulia R, Banjarnahor DT, Harianja RD, Yovi I. Bedaquiline Effect Towards QT Interval in Drug Resistant Tuberculosis (DR-TB): A Systematic Review. Siriraj Med J. 2023;75(9):638–45.

26. Ma Q, Li Z, Guo X, Guo L, Yu S, Yang H, et al. Prevalence and risk factors of prolonged corrected QT interval in general Chinese population. BMC Cardiovasc Disord. 2019;19(1):1–10.

27. Tanneau L, Karlsson MO, Rosenkranz SL, Cramer YS, Shenje J, Upton CM, et al. Assessing Prolongation of the Corrected QT Interval with Bedaquiline and

Delamanid Coadministration to Predict the Cardiac Safety of Simplified Dosing Regimens. Clin Pharmacol Ther. 2022;112(4):873–81.

28. Primadana V, Yovi I, Estiningsih DS. Bedaquiline Correlation to QT Interval Prolongation in DR-TB Patients. J Respirasi. 2022;8(3):140–6.

29. AlTaweel M. The Worst-Case Scenario of Electrolytes Imbalance, Cardiac Arrest, and Acquired Prolonged QT Interval: A Case Report and Literature Review. Online J Cardiol Res Reports. 2023;7(3):1–6.

30. Godwin IU, Atulomah N. Impact of Lifestyle Change Intervention on Tuberculosis Treatment Outcome in Tuberculosis Patients with Diabetes Mellitus Comorbidity in South West Nigeria. Texila Int J Public Heal. 2023;11(2).

31. Authors' Affiliations. All about Your Eyes. 2020;191–2.

32. Lin N, Zhang H, Li X, Niu Y, Gu H, Lu S, et al. The influence of different glucose tolerance on QTc interval: a population-based study [Internet]. BMC Cardiovasc Disord [Internet]. BioMed Central; 2023;23(1):1–7. Available from: https://doi.org/10.1186/s12872-023-03081-6

33. Pakan S. Petunjuk Teknis. 2007 p. 978–979.

34. Saifullah A, Mallhi TH, Khan YH, Iqbal MS, Alotaibi NH, Alzarea AI, et al. Evaluation of risk factors associated with the development of MDR-and XDR-TB in a tertiary care hospital: A retrospective cohort study. PeerJ. 2021;9:1–19.

35. Saleem Z, Ullah I, Awan MSBF, Tauqir J, Younis F, Khan N, et al. Distribution of Dr-Tb By Sex, Age Groups, Occupation, Province, Division, District, Type of Disease, Type of Drug Resistance, Treatment Regimen and Outcome of Treatment in Dr-Tb Population in D.I.Khan Division, Pakistan. Gomal J Med Sci. 2020;18(3):116–31.

36. Gupta H, Kant S, Jain A, Ahluwalia S, Natu SM. Association of Nutritional Factors with Tuberculosis Treatment Outcome. Natl Semin Appl Artif Intell Life Sci. 2013;6–13.

37. McQuaid CF, Sinha P, Bhargava M, Weerasuriya C, Houben RMGJ, Bhargava A. Tuberculosis and nutrition: what gets measured gets managed [Internet]. Lancet Respir Med [Internet]. Elsevier Ltd; 2023;11(4):308–10. Available from:

http://dx.doi.org/10.1016/S2213-2600(23)00009-7

38. Alvarez-Uria G, Midde M. Sex differences and factors influencing the duration of the QT interval in patients on anti-tuberculosis therapy [Internet]. Eur Respir J [Internet]. 2018;51(2). Available from: http://dx.doi.org/10.1183/13993003.02368-2017

39. Ritter JM. Cardiac safety, drug-induced QT prolongation and torsade de pointes (TdP). Br J Clin Pharmacol. 2012;73(3):331–4.

40. Lima-Leopoldo AP, Sugizaki MM, Leopoldo AS, Carvalho RF, Nogueira CR, Nascimento AF, et al. Obesity induces upregulation of genes involved in myocardial Ca2+ handling. Brazilian J Med Biol Res. 2008;41(7):615–20.

41. De Geest B, Mishra M. Role of Oxidative Stress in Diabetic Cardiomyopathy. Antioxidants. 2022;11(4).

42. Nieves-Cintrón M, Flores-Tamez VA, Le T, Baudel MMA, Navedo MF. Cellular and molecular effects of hyperglycemia on ion channels in vascular smooth muscle. Cellular and Molecular Life Sciences. 2021 p. 31–61.

43. Bacharova L, Kollarova M, Bezak B, Bohm A. Left Ventricular Hypertrophy and Ventricular Tachyarrhythmia: The Role of Biomarkers. Int J Mol Sci. 2023;24(4).

44. Maly J, Emigh AM, DeMarco KR, Furutani K, Sack JT, Clancy CE, et al. Structural modeling of the hERG potassium channel and associated drug interactions. Front Pharmacol. 2022;13(September):1–26.

45. Krishna S, Borrel A, Kleinstreuer N, Huang R, Zhao J, Xia M. High-Throughput Chemical Screening and Structure-Based Models to Predict hERG Inhibition. Biology (Basel). 2022;11(2).

46. Nguyen TMP, Nguyen BH, Hoang TTT, Nguyen HA, Vu DH, Nguyen MH, et al. Safety and effectiveness of all-oral and injectable-containing, Bedaquiline-based long treatment regimen for pre-XDR tuberculosis in Vietnam. Front Pharmacol. 2022;13(October):1–11.

47. Tse G, Li KHC, Cheung CKY, Letsas KP, Bhardwaj A, Sawant AC, et al. Arrhythmogenic Mechanisms in Hypokalaemia: Insights From Pre-clinical Models. Front Cardiovasc Med. 2021;8.

48. Wempe MF. New Insights into Ion Channels: Predicting hERG-Drug Interactions. Int J Mol Sci. 2022;23(18).

49. Arora N. Serum Chloride and Heart Failure [Internet]. Kidney Med [Internet]. The Author; 2023;5(4):100614. Available from: https://doi.org/10.1016/j.xkme.2023.100614